Epigenomic and Transcriptional Mechanisms in Cancer Progression and Therapy Response
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 115
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer progression is driven not only by genetic mutations but also by widespread changes in epigenomic regulation that alter transcriptional programs and cellular identity. Recent studies have revealed that tumor cells can dynamically rewire enhancer landscapes, transcription factor networks, and chromatin architecture to support proliferation, metastasis, and therapy resistance. Advances in genomic technologies, including single-cell sequencing, chromatin profiling, and 3D genome mapping, now enable detailed characterization of regulatory elements that control oncogenic transcriptional programs. These approaches have identified super-enhancers, enhancer hubs, and regulatory variants that play key roles in tumor development across multiple cancer types. In parallel, epigenetic regulators and transcriptional dependencies are emerging as promising therapeutic targets. This Special Issue will highlight recent advances in understanding how epigenomic plasticity and enhancer reprogramming contribute to tumor heterogeneity, disease progression, and treatment response. We welcome original research and review articles that integrate experimental and computational approaches to investigate chromatin regulation, gene regulatory networks, and epigenomic mechanisms underlying cancer biology.
Dr. Benjamin L. Kidder
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer progression
- genetic mutations
- epigenomic plasticity
- tumor heterogeneity
- gene regulatory networks
- epigenomic mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
